These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 26973271)

  • 1. Combination of Urinary Sodium/Creatinine Ratio and Plasma Brain Natriuretic Peptide Level Predicts Successful Tolvaptan Therapy in Patients With Heart Failure and Volume Overload.
    Sato Y; Dohi K; Watanabe K; Tanimura M; Takeuchi T; Sugiura E; Sugimoto T; Kumagai N; Ogura T; Nakamori S; Fujimoto N; Yamada N; Ito M
    Int Heart J; 2016; 57(2):211-9. PubMed ID: 26973271
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Short-term effects of low-dose tolvaptan on hemodynamic parameters in patients with chronic heart failure.
    Watanabe K; Dohi K; Sugimoto T; Yamada T; Sato Y; Ichikawa K; Sugiura E; Kumagai N; Nakamori S; Nakajima H; Hoshino K; Machida H; Okamoto S; Onishi K; Nakamura M; Nobori T; Ito M
    J Cardiol; 2012 Dec; 60(6):462-9. PubMed ID: 23068288
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urine sodium excretion after tolvaptan administration is dependent upon baseline serum sodium levels: a possible explanation for the improvement of hyponatremia with scarce chance of hypernatremia by a vasopressin receptor antagonist.
    Imamura T; Kinugawa K; Minatsuki S; Muraoka H; Kato N; Inaba T; Maki H; Hatano M; Yao A; Komuro I
    Int Heart J; 2014; 55(2):131-7. PubMed ID: 24632953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of tolvaptan on acute heart failure with hyponatremia--a randomized, double blind, controlled clinical trial.
    Shanmugam E; Doss CR; George M; Jena A; Rajaram M; Ramaraj B; Anjaneyan K; Kanagesh B
    Indian Heart J; 2016 Apr; 68 Suppl 1(Suppl 1):S15-21. PubMed ID: 27056648
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms of Diuresis for Acute Decompensated Heart Failure by Tolvaptan.
    Nomoto H; Satoh Y; Kamiyama M; Yabe K; Masumura M; Sakakibara A; Yamashita S; Suzuki M; Sugiyama T; Oumi T; Ohno M; Takahashi Y; Isobe M
    Int Heart J; 2017 Aug; 58(4):593-600. PubMed ID: 28701677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of tolvaptan in patients hospitalized for worsening chronic heart failure with severe hyponatremia: The initial experience at a single-center in Turkey.
    Sağ S; Aydın Kaderli A; Yıldız A; Gül BC; Özdemir B; Baran İ; Güllülü S; Aydınlar A; Çavuşoğlu Y
    Turk Kardiyol Dern Ars; 2017 Jul; 45(5):415-425. PubMed ID: 28694395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic administration of oral vasopressin type 2 receptor antagonist tolvaptan exerts both myocardial and renal protective effects in rats with hypertensive heart failure.
    Morooka H; Iwanaga Y; Tamaki Y; Takase T; Akahoshi Y; Nakano Y; Fujiki H; Miyazaki S
    Circ Heart Fail; 2012 Jul; 5(4):484-92. PubMed ID: 22628529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of Tolvaptan With or Without the Pre-Administration of Renin-Angiotensin System Blockers in Hospitalized Patients With Acute Decompensated Heart Failure.
    Adachi S; Miura SI; Shiga Y; Arimura T; Morii J; Kuwano T; Kitajima K; Iwata A; Morito N; Fujimi K; Yahiro E; Nishikawa H; Saku K
    Int Heart J; 2017 May; 58(3):385-392. PubMed ID: 28484118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of tolvaptan in patients with chronic kidney disease and chronic heart failure.
    Katsumata M; Hirawa N; Sumida K; Kagimoto M; Ehara Y; Okuyama Y; Fujita M; Fujiwara A; Kobayashi M; Kobayashi Y; Yamamoto Y; Saka S; Yatsu K; Fujikawa T; Toya Y; Yasuda G; Tamura K; Umemura S
    Clin Exp Nephrol; 2017 Oct; 21(5):858-865. PubMed ID: 28190113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Efficacy of Tolvaptan in Congestive Heart Failure Patients with and Without Hypoalbuminemia: A Pilot Study.
    Okabe T; Yakushiji T; Igawa W; Ono M; Kido T; Ebara S; Yamashita K; Yamamoto MH; Saito S; Hoshimoto K; Amemiya K; Isomura N; Araki H; Ochiai M
    Cardiovasc Ther; 2015 Oct; 33(5):275-81. PubMed ID: 26122275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tolvaptan Improves Prognosis in Responders with Acute Decompensated Heart Failure by Reducing the Dose of Loop Diuretics.
    Nakamura M; Sunagawa O; Kinugawa K
    Int Heart J; 2018; 59(1):87-93. PubMed ID: 29375117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blood Urea Nitrogen/Creatinine Ratio and Response to Tolvaptan in Patients with Decompensated Heart Failure: A Retrospective Analysis.
    Okayama D; Suzuki T; Shiga T; Minami Y; Tsuruoka S; Hagiwara N
    Am J Cardiovasc Drugs; 2015 Aug; 15(4):289-93. PubMed ID: 25940650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The short-term and long-term effects of tolvaptan in patients with heart failure: a meta-analysis of randomized controlled trials.
    Xiong B; Huang Y; Tan J; Yao Y; Wang C; Qian J; Rong S; Deng S; Cao Y; Zou Y; Huang J
    Heart Fail Rev; 2015 Nov; 20(6):633-42. PubMed ID: 26334632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial.
    Konstam MA; Gheorghiade M; Burnett JC; Grinfeld L; Maggioni AP; Swedberg K; Udelson JE; Zannad F; Cook T; Ouyang J; Zimmer C; Orlandi C;
    JAMA; 2007 Mar; 297(12):1319-31. PubMed ID: 17384437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renal and anti-aldosterone actions of vasopressin-2 receptor antagonism and B-type natriuretic peptide in experimental heart failure.
    Costello-Boerrigter LC; Boerrigter G; Cataliotti A; Harty GJ; Burnett JC
    Circ Heart Fail; 2010 May; 3(3):412-9. PubMed ID: 20176717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tolvaptan, an orally active vasopressin V(2)-receptor antagonist - pharmacology and clinical trials.
    Miyazaki T; Fujiki H; Yamamura Y; Nakamura S; Mori T
    Cardiovasc Drug Rev; 2007; 25(1):1-13. PubMed ID: 17445084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful Treatment of Congestive Heart Failure Due to Severe Aortic Valve Stenosis With Low Dose Tolvaptan in Elderly Patients.
    Takasu K; Miyazaki T; Negoro K; Yatsu S; Shimizu M; Murata A; Kato T; Suda S; Hiki M; Kasai T; Miyauchi K; Daida H
    Int Heart J; 2017 May; 58(3):378-384. PubMed ID: 28539565
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Retrospective Observational Study on Predictors of Body Weight and BNP Teduction in Cases of Tolvaptan Induction for Heart Failure].
    Shinoda R; Shinoda Y; Mori T; Yoshimura T
    Yakugaku Zasshi; 2021; 141(2):281-288. PubMed ID: 33518649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urine osmolality estimated using urine urea nitrogen, sodium and creatinine can effectively predict response to tolvaptan in decompensated heart failure patients.
    Imamura T; Kinugawa K; Minatsuki S; Muraoka H; Kato N; Inaba T; Maki H; Shiga T; Hatano M; Yao A; Kyo S; Komuro I
    Circ J; 2013; 77(5):1208-13. PubMed ID: 23318562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vasopressin V2 receptor antagonist tolvaptan is effective in heart failure patients with reduced left ventricular systolic function and low blood pressure.
    Suzuki S; Yoshihisa A; Yamaki T; Sugimoto K; Kunii H; Nakazato K; Abe Y; Saito T; Ohwada T; Suzuki H; Saitoh S; Kubota I; Takeishi Y;
    Int Heart J; 2015; 56(2):213-8. PubMed ID: 25740399
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.